A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

PHASE3TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

Crisaborole 2%

Crisaborole 2% ointment

Trial Locations (11)

734-0023

Shirao Clinic of Pediatrics and Pediatric Allergy, Hiroshima

066-0021

Chitose dermatology and plastic surgery clinic, Chitose Shi

080-0013

Takagi Dermatological Clinic, Obihiro

674-0068

Yoshimura Child Clinic, Akashi

658-0082

Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic, Kobe

861-3101

Noguchi Dermatology Clinic, Kamimashiki-gun

572-0838

Yoshioka Dermatology Clinic, Neyagawa

120-0034

Mildix Skin Clinic, Adachi-ku

158-0097

Yoga Allergy Clinic, Setagaya-ku

170-0002

Sugamo Kobayashi Derma Clinic, Toshima-Ku

814-0171

Hoshikuma Dermatology・Allergy Clinic, Fukuoka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY